Most Recent
Three law firms are meeting employee demand for workplaces that prioritise social engagement, scoring spots on the top 40 Australian workplaces to give back to the community.
The law firm that secured a $44.5 million settlement in a class action against Woolworths has won its full $14.5 million in costs, with a judge tossing the report of the referee he appointed to examine the fees, which he said appeared double what they should be.
A judge has raised concerns about the utility of referring a satellite dispute over whistleblower protections to the Full Court in a $13 million lawsuit brought by an ex-Greenwoods & Herbert Smith Freehills partner.
For many in the legal profession the choice of Justice Jayne Jagot to replace the outgoing Justice Patrick Keane on the High Court, heralding a new era of judicial diversity on the top bench, was hardly a surprise.
The Australian Securities and Investments Commission has suffered a defeat in proceedings alleging the Commonwealth Bank of Australia accepted conflicted remuneration through the sale of its Essential Super product, with a judge finding the regulator "ignored the circumstances" in which the product was distributed.
Property owners are fighting arguments that claims in a class action over allegedly combustible cladding do not fall under a $190 million insurance policy's definition of property damage, saying installing the cladding was like “dousing one’s house in kerosene”.
A judge has suggested that financial services giant AMP bring an application for summary dismissal of part of a class action over allegedly excessive insurance premiums, questioning the basis for the claims.
A former Greenwoods & Herbert Smith Freehills partner wants the Full Court to decide whether whistleblower protections apply retrospectively in a $13 million suit alleging he was sacked for complaining about the tax avoidance strategy of construction giant Lendlease.
The High Court will take up Meta's challenge to the privacy commissioner's case over the Cambridge Analytica data breach, giving the court the chance to rule on the jurisdictional reach of Australian regulators in their pursuit of US tech giants.
German biotech Fresenius Kabi has struck back at Samsung Bioepis's latest attack on the validity of its patents for a liquid formulation of top selling immunosuppressant drug Humira, accusing the Korean company of causing its sales to flag by infringing the patent.